DGAP-News

STRATEC accelerates growth in first half of 2014

DGAP-News: STRATEC Biomedical AG / Key word(s): Half Year
Results/Interim Report
STRATEC accelerates growth in first half of 2014

23.07.2014 / 07:35

---------------------------------------------------------------------

STRATEC accelerates growth in first half of 2014

- Sales of EUR 69.1 million in 6M/2014
(+14.9%; 6M/2013: EUR 60.1 million)
- EBIT of EUR 11.2 Million** in 6M/2014
(+36.0%; 6M/2013: EUR 8.3 million)
- EBIT margin of 16.3%** in 6M/2014
(+260 base points; 6M/2013: 13.7%)
- Consolidated net income of EUR 9.6 Million** in 6M/2014
(+47.3%; 6M/2013: EUR 6.5 million)
- Earnings per share of EUR 0.82** in 6M/2014
(+46.4%; 6M/2013: EUR 0.56)

Birkenfeld, July 23, 2014

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard,
TecDAX) today announced its results for the period from January 1, 2014 to
June 30, 2014 upon the publication of its Interim Report as of June 30,
2014.

Key figures (EUR 000s)    01.01.- 06.30.2014   01.01.- 06.30.2013*   Change

Sales                                 69,050                60,071   +14.9%

EBIT                                11,232**                 8,257   +36.0%

EBIT margin (%)                       16.3**                  13.7 +260 BPS

Consolidated net income              9,635**                 6,543   +47.3%

Earnings per share (EUR)              0.82**                  0.56   +46.4%

* The accounting methods used in the consolidated financial statements
were amended in line with IAS 8 in the 2013 financial year. Reference is
made in this respect to the information in the Annual Report 2013 in
Section A of the notes to the consolidated financial statements.

** 2014 figure adjusted to exclude a one-off item resulting from
recognition in the first quarter of expenses for the remaining years of the
term of a management board contract for a retired member of the Board of
Management. Unadjusted EBIT amounts to EUR 10.3 million, the corresponding
EBIT margin amounts to 14.9%, consolidated net income to EUR 8.9 million
and earnings per share to EUR 0.76. The effective amount of the liability
due may differ at the time of payment.


Financial performance
STRATEC generated sales growth of 14.9% in the first six months of the 2014
financial year. This sales performance, which remains slightly ahead of
budget, was chiefly driven by growth with established systems. An
increasing share of growth was also attributable to systems recently
launched onto the market by our customers. The figures include a small